AddictionCare 2025: Drug Addiction and Rehabilitation

Barry I Gold Profile

Barry I Gold

Barry I Gold

Biography

Barry I. Gold is a pharmacologist with a distinguished career spanning academia, the pharmaceutical industry, and authorship. He earned a B.S. in zoology from the University of Cincinnati and a Ph.D. in pharmacology from Boston University, followed by three years of postdoctoral research at Yale University. After his time at Yale, he began his academic career as an Assistant Professor of Pharmacology at the Uniformed Services University of the Health Sciences, serving from 1979 to 1984. He then transitioned to the pharmaceutical industry, where he held several senior roles: Director of Biochemistry at Anaquest, a division of the BOC Corporation (1984?1989); Director of Project Management at Wyeth-Ayerst, a division of American Home Products (1989?1994); and Director of Project Management at Knoll Pharmaceutical, a division of BASF (1994?2002). During his time in the industry, he managed a biochemistry laboratory and oversaw international drug development projects.

Upon retiring from the pharmaceutical sector in 2002, Dr. Gold began a new chapter as a writer. He has authored three books?We?re Overdosed, Boomer Dad, and The Fourth?and contributed essays to various online journals. He resides in Oakland, New Jersey, where he lives alone. He has two adult children from his first marriage and a teenage child from his second.

Research Interest

Barry I Gold is a pharmacologist

Abstract

Managing Drug Distribution I focus on drug distribution in the U.S. because it is distribution that initiated the drug overdose epidemic. Currently, drug prescriptions in the U.S. is managed at the state level. As a result, there are fifty state records that have to be collected. I also propose that TV advertisement of prescription drugs should be stopped. It moves control of prescriptions to patients rather that medical staff. I propose that drug distribution in the U.S. be centralized. That is, law enforcement, regulatory affairs, science and licensing be consolidated into a single function. That would not only streamline data collection, it would provide a multidisciplinary approach to problem solving and generate new ideas more freely. It would provide a Team approach to drug management. Finally, I look forward to answering the questions, why did the deathrate increase and why has it begun to decrease?